Company intelligence / Profile preview

Mersana Therapeutics

Cambridge, Massachusetts, United Statesmersana.com ↗

Ownership: Public · MRSN
Employees: ~102
Development stage: Phase 1

Overview

Mersana’s lead candidate Emi-Le/XMT–1660 is a Dolasynthen-based B7-H4-targeting ADC currently in ongoing Phase I dose expansion studies. The maximum tolerated dose has not yet been established; initial safety/tolerability/efficacy data are expected in the second half of the year. The Immunosynthen-based HER2-targeting candidate XMT–2056 resumed its Phase I trial after a clinical hold was lifted; patient enrollment continues with GSK holding an exclusive global license option. Additional candidates are at preclinical stages or partnered with major pharma companies.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugates (ADCs), including cytotoxic and immunostimulatory ADCs
Industry: Biotech

Drug pipeline

11 assets

upifitamab rilsodotin

10 more assets in the full pipeline.

Request access →

Partnerships

Johnson & Johnson/Janssen Biotech – discovery/development of novel Dolasynthen-based ADCs for up to three targetsMerck KGaA – discovery/development of novel Immunosynthen-based ADCs for up to two targetsGSK plc – exclusive global license option on XMT–2056Ares Trading S.A.Asana Biosciences LLC.

Financials

Market cap: $145.4M
Total revenue: $11M
Enterprise value: $91.3M

Beyond the preview

Go deeper on Mersana Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mersana Therapeutics.

Explore the full profile